Investors in
Becton, Dickinson and Company (BDX) have generated
a return of 26% over the past five years. The company has been
stagnating and navigating through
macroeconomic headwinds, yet it is perceived as a
Strong Value Stock by analysts. Despite large decreases in short interest and guidance falling short of expectations, BDX's
earnings and revenue estimates have consistently been surpassed. Positive fiscal outcomes have included multiple quarters where earnings estimates have been exceeded and raised, leading to solid Q1 and Q2 earnings.
BDX also received
FDA approval for their test, suggesting wider testing access. Experts recommend investors to hold the
BDX bag, especially for
long-term value. Recent news suggests
Becton Dickinson has entered into a partnership with
Helmer Scientific, which is viewed as a push for their Medical Management Solutions.
BDX has been named among
Fortune's Most Innovative Companies and was recognized for its employee well-being.
Becton Dickinson and BDX News Analytics from Mon, 24 Jul 2023 07:00:00 GMT to Sat, 18 May 2024 20:40:39 GMT -
Rating 6
- Innovation 8
- Information 8
- Rumor -2
